AlphaCrest Capital Management’s Fate Therapeutics FATE Stock Holding History

AlphaCrest Capital Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12,823	Closed	-$287K	–	404
2022 Q3	$287K	Buy	+12,823	New	+$371K	0.02%	1152
2021 Q4	–	Sell	-7,147	Closed	-$424K	–	1386
2021 Q3	$424K	Sell	7,147 -8,746	-55%	-$686K	0.02%	979
2021 Q2	$1.38M	Buy	15,893 +12,866	+425%	+$1.04M	0.06%	509
2021 Q1	$250K	Buy	+3,027	New	+$290K	0.01%	1077
2020 Q4	–	Sell	-10,500	Closed	-$420K	–	1163
2020 Q3	$420K	Buy	+10,500	New	+$367K	0.05%	691
2020 Q2	–	Sell	-9,460	Closed	-$210K	–	969
2020 Q1	$210K	Buy	+9,460	New	+$239K	0.03%	922

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AlphaCrest Capital Management's FATE Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 12,823 shares — an estimated $287K sold.

AlphaCrest Capital Management first reported a position in FATE in Q1 2020 and held it in 6 quarters. The position peaked at $1.38M in Q2 2021. 228 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

AlphaCrest Capital Management reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 12,823 Fate Therapeutics shares in Q4 2022, an estimated $287K.
AlphaCrest Capital Management first reported a position in Fate Therapeutics in Q1 2020 and held it in 6 quarters.
AlphaCrest Capital Management's Fate Therapeutics position peaked at $1.38M in Q2 2021.
228 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.